Off-label promotion, on-target sales

PLoS Medicine

Volumn 5, Issue 10, 2008, Pages 1432-1435

  Fugh Berman, Adriane ^a   Melnick, Douglas ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BROMFENAC; FENFLURAMINE; GABAPENTIN; MISOPROSTOL; PHENTERMINE; RANIBIZUMAB; ROFECOXIB;

CANCER THERAPY; CARDIOVASCULAR DISEASE; COLON POLYP; CONTINUING EDUCATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HUMAN; LIVER FAILURE; MEDICAL EDUCATION; MEDICAL INFORMATION; OFF LABEL DRUG USE; PAIN; PRESCRIPTION; PUBLIC HEALTH; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; ULCER; ARTICLE; DRUG LABELING; DRUG UTILIZATION; METHODOLOGY; STANDARD;

DRUG INDUSTRY; DRUG LABELING; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS;

EID: 55949133786     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050210     Document Type: Review

References (16)

1. Hampton T (2007) Experts weigh in on promotion, prescription of off-label drugs. JAMA 297: 683-684.
2. Goldberg AB, Greenberg MB, Darney PD (2001) Misoprostol and pregnancy. N Engl J Med 344: 38-47.
3. Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166: 1021-1026.
4. General Accounting Office (2001) Drug safety: Most drugs withdrawn in recent years had greater health risks for women. GAO-01-286R. Available: http://www.gao.gov/new.items/d01286r.pdf. Accessed 23 September 2008.
5. Stafford RS, Radley DC (2003) National trends in antiobesity medication use. Arch Intern Med 163: 1046-1050.
6. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, et al. (2006) Off-label use of medicines: Consensus recommendations for evaluating appropriateness. Med J Aust 185: 544-548.
7. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
8. Cinquegrana J, Lloyd DK (2006) Legal: Shifting perspective on off-label promotion. Pharmaceutical Executive. Available: http://pharmexec.findpharma.com/ pharmexec/article/articleDetail.jsp?id=282490. Accessed 23 September 2008.
9. Weeks AD, Fiala C, Safar P (2005) Misoprostol and the debate over off-label drug use. BJOG 112: 269-272.
10. Muir H (2006) Medical roulette: Dicing with death. New Sci 191: 38-41.
11. Baghdadi R (2007) An eye for an eye: Lucentis and the new value system for pharmaceuticals. RPM Report 2: 1-5.
12. Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: The promotion of gabapentin: An analysis of internal industry documents. Ann Intern Med 145: 284-293.
13. Committee on Finance United States Senate (2007) Use of educational grants by pharmaceutical manufacturers. Available: http://www.acme-assn.org/ home/prb042507a.pdf. Accessed 23 September 2008.
14. Arnold M (2005) Flexible forces. Medical Marketing Media 11: 40.
15. Niles S (2006) A matter of trust. Med Ad News 12: 1.
16. Wasserstein JN, Powell BF (2008) Another brick in the wall - DC enacts law regulating pharmaceutical marketing. Regulatory Focus. Available: http://www.fdalawblog.net/fda_law_blog_hyman_phelps/files/ regulatory_focus_article.pdf. Accessed 23 September 2008.